Compare Stitch Fix Inc (SFIX) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Stitch Fix Inc vs Sanofi SA — how do they compare? Stitch Fix Inc trades at $3.94 (market cap $520.36M), while Sanofi SA trades at $44.05 (market cap $104.83B). The key difference: Sanofi SA is far larger — about 201.5× Stitch Fix Inc's market cap, and Sanofi SA pays a 5.5% dividend while Stitch Fix Inc pays none. Which is the better fit depends on your goals.
| SFIX | SNY | |
|---|---|---|
Market Cap | $520.36M | $104.83B |
Sector | Consumer Cyclical | Health |
52-Week High | $5.83 | $52.34 |
52-Week Low | $3.06 | $41.33 |
Enterprise Value | $408.08M | $121.32B |
Dividend Yield | — | 5.5% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Stitch Fix Inc
Stitch Fix Inc offers personal style service for men and women. The company engages in delivering one-to-one personalization to clients through the combination of data science and human judgment. It provides a shipment service called A FIX where the stylist's hand selects items from several merchandises with analysis of client and merchandise data to provide a personalized shipment of apparel, shoes, and accessories suited to the client's needs. The company offers products across categories, brands, product types and price points including Women's, Petite, Maternity, Men's and Plus. It also offers various product types, including denim, dresses, blouses, skirts, shoes, jewelry and handbags, and sells merchandise across various range of price points.
Read more on SFIX →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
